Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2000-04-12
2002-02-19
Whisenant, Ethan (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S024100
Reexamination Certificate
active
06348316
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates generally to the fields of autoimmunity and inflammatory bowel disease and more specifically to the development of pouchitis in patients with ulcerative colitis.
2. Background Information
Inflammatory bowel disease (IBD) is the collective term used to describe two gastrointestinal disorders of unknown etiology: Crohn's disease (CD) and ulcerative colitis (UC). The course and prognosis of IBD, which occurs world-wide and is reported to afflict as many as two million people, varies widely. Onset of IBD is predominantly in young adulthood with diarrhea, abdominal pain, and fever the three most common presenting symptoms. The diarrhea may range from mild to severe and in ulcerative colitis often is accompanied by bleeding. Anemia and weight loss are additional common signs of IBD. Ten percent to fifteen percent of all patients with IBD will require surgery over a ten year period. In addition, patients with IBD are at increased risk for the development of intestinal cancer. Reports of an increasing occurrence of psychological problems, including anxiety and depression, are perhaps not surprising symptoms of what is often a debilitating disease that strikes people in the prime of life.
Progress has been made in diagnosing IBD and in distinguishing, in many cases, Crohn's disease from ulcerative colitis. However, Crohn's disease and ulcerative colitis each can represent a collection of heterogeneous disease types that affect the gastrointestinal tract and produce similar symptoms. One aspect of the heterogeneity associated with inflammatory bowel disease is revealed by the stark contrast in outcomes seen following colectomy for treatment of uncontrolled ulcerative colitis. The preferred procedure is abdominal colectomy with ileal pouch anal anastomosis (IPAA), whereby the diseased colonic mucosa is removed while continence is maintained through creation of an ileal reservoir or “pouch.” Although a subgroup of ulcerative colitis patients experience a favorable outcome following surgery, in the ten years after surgery almost 50% develop “pouchitis,” an inflammation of the pouch that can mimic the original symptoms of ulcerative colitis. In some patients, the recurrent symptoms of pouchitis are as debilitating as the symptoms present prior to surgery. Thus, for those who suffer from recurrent or “chronic” pouchitis, surgical treatment of ulcerative colitis provides little or no therapeutic value.
A genetic method of determining the subgroup of ulcerative colitis patients at increased risk for development of pouchitis or chronic pouchitis would be useful in the medical management of these patients following surgery and in identifying good candidates for surgical treatment. Unfortunately, a genetic method for predicting the development of pouchitis or chronic pouchitis currently is not available. Thus, there is a need for a convenient and non-invasive genetic method of determining the risk of developing pouchitis or chronic pouchitis following pouch surgery. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The present invention provides a method of determining a risk of pouchitis development following a surgical procedure where an internal pouch is created in a patient with ulcerative colitis. The method is practiced by determining in the patient the presence or absence of a pouchitis-associated allele linked to an interferon &ggr; receptor locus, where the presence of the pouchitis-associated allele indicates an increased risk of pouchitis development. The interferon &ggr; receptor locus to which the pouchitis-associated allele is linked can be, for example, an interferon &ggr; receptor 1 gene. A pouchitis-associated allele useful in the invention can be, for example, an allele located within the sixth intron of the interferon &ggr; receptor 1 gene, such as the FA1 microsatellite 171 allele. In one embodiment, the pouchitis-associated allele is associated with chronic pouchitis with an odds ratio of at least 4 and a lower 95% confidence limit greater than 1. The methods of the invention can be useful in identifying good candidates for surgical treatment of ulcerative colitis and in the selective medical management of high risk patients following surgery, as described further below.
In a preferred embodiment, the invention provides a method of determining a risk of chronic pouchitis development following ileal pouch anal anastomosis in a patient with ulcerative colitis. In this method, one determines the presence or absence of an interferon &ggr; receptor 1 FA1 microsatellite 171 allele in the patient, and the presence of the 171 allele indicates an increased risk of chronic pouchitis development.
In another embodiment, a method of the invention for determining a risk of pouchitis development in a patient with ulcerative colitis is practiced by obtaining from the patient material which contains nucleic acid including the FA1 microsatellite locus of the interferon &ggr; receptor 1 gene; and enzymatically amplifying the nucleic acid to produce an amplified fragment containing the FA1 microsatellite locus, where the presence of the FA1 microsatellite 171 allele indicates an increased risk of pouchitis development. If desired, one can further include a step of electrophoresing the amplified fragment to determine whether a FA1 microsatellite 171 allele is present.
REFERENCES:
patent: 5221789 (1993-06-01), Novick et al.
patent: 5937862 (1999-08-01), Targan et al.
patent: 6033864 (2000-03-01), Braun et al.
patent: WO94/14467 (1994-07-01), None
patent: WO95/16036 (1995-06-01), None
patent: WO99/37682 (1999-07-01), None
Facklis et al., Diseases of the Colon and Rectum 42 (5) : 601-605 (May 1999).*
Plevy et al., Gastroenterology 110(4) : 1053-1060 ( Abstract only—1996).*
Merlin et al., “The Gene for the Ligand Binding Chain of the Human Interferon Gamma Receptor,”Immunogenetics45:413-421 (1997).
Meagher et al., “J Ileal Pouch-anal Anastomosis for Chronic Ulcerative Colitis: Complications and Long-term Outcome in 1310 Patients,”British Journal of Surgery85:800-803 (1998).
Carter et al., “Association of the Allele 2 of the Interleukin-1 Receptor Antagonist Gene with Ulcerative Colitis Requiring Colectomy and Pouchitis,”Gut44 (4S):A50 (1999).
GenBank Accession No.: AL050337, Human DNA Sequence from clone 503F13.
GenBank Accession No.: J03143, Human Interferon Gamma Receptor mRNA, complete cds.
GenBank Accession No.: NM_005534,Homo sapiensinterferon gamma receptor 2 mRNA.
GenBank Accession No.: U84721,Homo sapiensinterferon gamma receptor 1 gene.
Aitola et al., “Chronic inflammatory changes in the pouch mucosa are associated with cholangitis found on peroperative liver biopsy specimens at restorative protocolectomy for ulcerative colitits,”Scan. J. Gastroenterol. 33:289-293 (1998).
Altare et al., “A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFN&ggr; in a compound heterozygous child,”Am. J. Hum. Genet. 62:723-726 (1998).
Aparicio-Pages et al., “In vitro cellular cytotoxicity in Crohn's disease and ulcerative colitis: Relation with disease activity and treatment, and the effect of recombinant gamma-interferon,”J. Clin. Lab. Immunol. 29:119-124 (1989).
Binder, “Pouchitis—Predictable by immunological or genetic markers?”Eur. J. Gasteroent.&Hepatol., 8:943-945 (1996).
Bode et al., “IL-1&bgr; and TNF-&agr;, but not IFN-&agr;, IFN-&ggr;, IL-6 or IL-8, are secretory mediators in human distal colon,”Cytokine10:457-465 (1998).
Brett et al., “Genetic and immunological markers in pouchitis,”Eur. J. Gastroenterol. Hepatol. 8:951-955 (1996).
Camoglio et al., “Altered expression of interferon-&ggr; and interleukin-4 in inflammatory bowel disease,”Inflamm. Bowel Dis. 4:285-290 (1998).
Dib et al., “A comprehensive genetic map of the human genome based on 5,264 microsatellites,”Nature380:152-154 (1996).
Dumonceau et al., “Detection of fastidious mycobacteria in human intestines by the polymerase chain reaction,”Eur
Fleshner Phillip R.
Rotter Jerome I.
Taylor Kent D.
Yang Huiyang
Campbell & Flores LLP
Cedars-Sinai Medical Center
Whisenant Ethan
LandOfFree
Genetic testing for determining the risk of pouchitis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetic testing for determining the risk of pouchitis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic testing for determining the risk of pouchitis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2961615